Drug interactions
Larotrectinib + Repaglinide
Severity: Minor
Larotrectinib and Repaglinide: minor interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Larotrectinib is a modest CYP3A4 inhibitor and may increase repaglinide exposure. This could increase the risk of hypoglycemia.
What this interaction means in plain words
Larotrectinib and Repaglinide have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.
Larotrectinib belongs to Oncology; Repaglinide belongs to Endocrine.
Why it happens
Inhibition of CYP3A4-mediated metabolism of repaglinide.
What to do
Monitor blood glucose when larotrectinib is started and reduce the repaglinide dose if hypoglycemia occurs.
What to ask your pharmacist
- Is there anything I should notice while taking both?
- Do I need to tell my doctor at the next visit?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Larotrectinib and Repaglinide, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Repaglinide
- Gemfibrozil + Repaglinide Contraindicated
- Clarithromycin + Repaglinide Major
- Clopidogrel + Repaglinide Major
- Cobicistat + Repaglinide Major
- Cyclosporine + Repaglinide Major
- Cyclosporin + Repaglinide Major
Other interactions of Larotrectinib
Frequently asked questions
Can I take Larotrectinib with Repaglinide?
MediHelp rates the interaction as minor. Larotrectinib and Repaglinide have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. Larotrectinib is a modest CYP3A4 inhibitor and may increase repaglinide exposure. This could increase the risk of hypoglycemia.
How serious is the interaction between Larotrectinib and Repaglinide?
MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor blood glucose when larotrectinib is started and reduce the repaglinide dose if hypoglycemia occurs.
What other medicines interact with Repaglinide?
MediHelp also lists interactions of Repaglinide with, for example, Gemfibrozil, Clarithromycin, Clopidogrel. The full list is on the Repaglinide page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
